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Abstract
Background: Tuberculosis control program of Rwanda is currently phasing in light emitting diode-fluorescent
microscopy (LED-FM) as an alternative to Ziehl-Neelsen (ZN) smear microscopy. This, alongside the newly
introduced Xpert (Cepheid, Sunnyvale, CA, USA) is expected to improve diagnosis of tuberculosis and detection of
rifampicin resistance in patients at health facilities. We assessed the accuracy of smear microscopy and the
incremental sensitivity of Xpert at tuberculosis laboratories in Rwanda.
Methods: This was a cross-sectional study involving four laboratories performing ZN and four laboratories
performing LED-FM microscopy. The laboratories include four intermediate (ILs) and four peripheral (PLs)
laboratories. After smear microscopy, the left-over of samples, of a single early-morning sputum from 648
participants, were tested using Xpert and mycobacterial culture as a reference standard. Sensitivity of each test was
compared and the incremental sensitivity of Xpert after a negative smear was assessed.
Results: A total of 96 presumptive pulmonary tuberculosis participants were culture positive for M. tuberculosis. The
overall sensitivity in PL of ZN was 55.1 % (40.2–69.3 %), LED-FM was 37 % (19.4–57.6 %) and Xpert was 77.6 % (66.
6–86.4 %) whereas in ILs the same value for ZN was 58.3 % (27.7–84.8 %), LED-FM was 62.5 % (24.5–91.5 %) and
Xpert was 90 (68.3–98.8 %). The sensitivity for all tests was significantly higher among HIV-negative individuals (all
test p <0.05). The overall incremental sensitivity of Xpert over smear microscopy was 32.3 %; p < 0.0001. The
incremental sensitivity of Xpert was statistically significant for both smear methods at PL (32.9 %; p = 0.001) but not
at the ILs (30 %; p = 0.125) for both smear methods.
Conclusions: Our study findings of the early implementation of the LED-FM did not reveal significant increment in
sensitivity compared to the method being phased out (ZN). This study showed a significant incremental sensitivity
for Xpert from both smear methods at peripheral centers where majority of TB patients are diagnosed. Overall our
findings support the recommendation for Xpert as an initial diagnostic test in adults and children presumed to
have TB.
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Background
Despite the recommendations of the World Health
Organization to use Xpert [1] as a first line diagnostic
test, smear microscopy remains the most available and
affordable test in low-income countries. Microscopy is
inexpensive and highly specific in areas where there is a
high prevalence of tuberculosis. However, it has several
limitations including the fact that it is examiner-, tech-
nique-, and prevalence-dependent and in addition, it
lacks sensitivity [2].
Studies evaluating the performance of LED-FM have
shown that in addition to higher sensitivity (an average
of 10 % higher than conventional ZN), it had qualitative,
operational and cost advantages over both the conven-
tional FM and ZN. On the basis of these findings, the
World Health Organization (WHO) recommended in
2011 to replace conventional FM with LED-FM and
phase in LED-FM as an alternative to ZN microscopy
[3]. On the other hand, in 2010 WHO recommended
that Xpert be used at district and sub-district levels as
the initial diagnostic test in individuals suspected of hav-
ing MDR-TB or HIV-associated tuberculosis. The WHO
further updated recommendations on the use of Xpert
including a follow-on test for smear-negative patients in
other settings [1]. In a Cochrane meta-analysis, sensitiv-
ity and specificity of Xpert compared with culture were
88 % (95 % CI 83 to 92 %) and 98 % (97 to 99 %), among
smear-positive cases, and 98 % (97 to 99 %) and 68 %
(60 to 75 %) among smear-negative cases [4].
In Rwanda, the national tuberculosis control program
has started the phase-in of LED-FM as an alternative to
ZN microscopy in peripheral (PLs) and intermediate
health facility laboratories (ILs). To date, 40 % of labora-
tories have implemented LED-FM and 16 health facil-
ities started using Xpert for TB detection in 2012. A
sample transportation system was organized to facilitate
transfer of samples from health facilities without an
Xpert machine. The ILs or district hospital laboratories
have an average of six qualified laboratory technologists
and they are supervised, trained and mentored by the
National Reference Laboratory (NRL) whereas peripheral
laboratories or health center laboratories have an aver-
age of two laboratory technicians and they are subse-
quently supervised, trained and mentored by ILs. In
regards to the workload, PLs test more than 75 % of pul-
monary tuberculosis presumptive yet most of these facil-
ities have very few technologists who also perform other
requested laboratory tests. Based on the countrywide
data of external quality assurance of smear microscopy
(annual blind rechecking and proficiency panel test), the
results of PLs tend to be better than those of ILs. How-
ever, no study of accuracy has been done to assess the
significance of this difference. Therefore, this study
aimed to determine the sensitivity of smear microscopy
and the incremental gain of Xpert for the detection of
pulmonary tuberculosis at PLs and ILs to support the
scale up of this new molecular technology. The present
study assessed the performance of the two sputum
smear microscopy techniques and the incremental yield
of Xpert over microscopy among individuals with pre-
sumptive pulmonary tuberculosis, taking mycobacterial
culture as the reference standard.
Methods
Setting, study design and population
This was a cross-sectional study involving eight health
facilities which were purposively selected due to the high
numbers of presumptive pulmonary tuberculosis re-
corded in the year 2013. Four PLs (two performing ZN
and two performing LED-FM) and four intermediate la-
boratories (two performing ZN and two preforming
LED-FM). Based on quality control of smear microscopy
(QC) data of 2012 and 2013 these eight laboratories per-
formed equally well, though the QC for intermediate is
performed by the NRL whereas QC for peripheral are
subsequently done by ILs.
After smear microscopy, the left-over of the samples,
of a single early-morning sputum from 648 new pre-
sumptive pulmonary tuberculosis patients, were tested
using Xpert and mycobacterial culture as a reference
standard.
Laboratory procedures
For each eligible participant, three to five mL of morning
sputum specimen were collected in a clean plastic con-
tainer with wide-mouthed, screw-capped and leak proof.
A direct sputum smear was prepared, stained and exam-
ined by laboratory technicians at health facility labora-
tory. The left-over of sputum specimens and the
examined corresponding sputum smear were immedi-
ately shipped to the tuberculosis laboratory of NRL. Spu-
tum specimens not shipped immediately were
refrigerated (4 to 8 °C). All sputum specimens collected
were transported in a cool box (4–8 °C) and were proc-
essed on the same day at NRL TB laboratory.
At the NRL, sputum specimens were recorded and
decontaminated using N-Acetyl-L-Cysteine Sodium hy-
droxide (NALC-NaOH) procedure followed by
neutralization with phosphate buffer, centrifuged and the
deposits (0.5 ml) inoculated in Mycobacterial growth in-
dicator tube (BBL MGIT, Becton and Dickson, Franklin
Lakes, NJ USA) and two Home-made Lowenstein Jensen
(LJ) tubes respectively. The remaining pellet was used to
prepare a smear and to run Xpert. For Xpert 0.5 mL of
decontaminated and concentrated sputum was added to
1.5 mL of the sample reagent (i.e., a ratio of 1:3). After
15 min, two mL of the mixture was added to the Xpert
cartridge and then run in the machine in accordance
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with manufacturer’s guide (Cepheid, Sunnyvale, CA,
USA). The smears prepared from pellet were stained
using auramine for LED-FM examination and NRL re-
sults were considered final for those who tested negative
at the health facility. Inoculated MGIT were incubated
in an automated BD BACTEC 960 machine for up to
42 days according to manufacturer’s guide (MGIT, Bec-
ton and Dickson, Franklin Lakes, NJ USA) while the two
LJ tubes were incubated in manual incubator at 37 °C
and inspected weekly for up to eight weeks. Positive cul-
tures were confirmed for presence of acid fast bacilli by
ZN microscopy and strain identification was done using
an immunochromatographic test (SD MPT64TB Ag kit;
SD Bioline, South Korea). Reexamination of smear from
health facility at NRL, results of concentrated smear and
Xpert provided preliminary results for treatment of pul-
monary tuberculosis cases missed by health facility la-
boratories. The final results were provided by
Mycobacterial culture.
Data management and analysis
As the presence of MTB cannnot be excluded among
contaminated cultures and cultures positive for non tu-
berculous mycobacterial (NTM), these results were ex-
cluded from the analysis as they may have led to an
under-estimation of the sensitivity of Xpert or smear mi-
croscopy. The sensitivity and specificity was calculated
for each method and type of health facility stratified by
HIV-status using MGIT and/or LJ culture as gold stand-
ard. The incremental sensitivity of Xpert test to smear
microscopy method was defined as the percentage of
smear microscopy negative but Xpert positive by health
facility among culture positive for M. tuberculosis. The
McNemar statistical test was used to assess the signifi-
cance of the differences in results obtained from smear
microscopy using ZN versus LED-FM and the incremen-
tal sensitivity of Xpert. Based on these results, we com-
pared the effectiveness of diagnostic strategies to
propose the most accurate algorithm for the diagnosis of
pulmonary tuberculosis at PLs and ILs. A p-value <0.05
was considered statistically significant. All data analysis
was performed using SPSS version 21.0 software
(Armonk, NY: IBM Corp.).
Results
Participants’ characteristics and microbiological profile
Among the 648 patients enrolled, 48 were excluded for
analysis due to incomplete results (23; 3.5 % contami-
nated cultures, 22; 3.4 % cultures positive for NTMs and
3; 0.5 % invalid Xpert results). Of the 600 included, 372
(62 %) were male and median age was 37 years (inter-
quartile range 28–50). A total of 390 (65.0 %) and 210
(35.0 %) participants were from PLs and ILs respectively
of whom, 318 (53 %) were from laboratories performing
ZN and 282 (47 %) from laboratories performing LED-
FM microscopy, Fig. 1.
The prevalence of HIV in this study population was
162 (27.0 %). The smear positivity rates were 12.0 %
and 5.0 % among ZN and LED-FM laboratories re-
spectively, whereas the positivity rate for Xpert was
13.7 % of whom seven (1.2 %) had rifampicin resist-
ant M. tuberculosis. A total of 96 (16.0 %) partici-
pants had culture confirmed TB of whom 28 (29.2 %)
were HIV-infected, Table 1.
Senstivity of smear methods and Xpert assay
Among 96 culture positive for M. tuberculosis by MGIT
and/or LJ method, 47 (49.0 %) were smear negative of
which 20 (42.6 %) were tested with LED-FM and 27
(57.4 %) with ZN. Among 82 patients found MTB posi-
tive with the Xpert assay, 36 (43.9 %) were smear mi-
croscopy negative of whom 13 (36.1 %) were HIV-
infected. In regard to rifampicin resistance, seven rifam-
picin resistant MTB cases were detected by Xpert,
among which only two were smear positive. The overall
sensitivity of Xpert was 80.2 %, 95%CI (70.8–87.6). Xpert
at PLs had a sensitivity of 77.6 %, 95%CI (66.6–86.4) as
compared to 90 %, 95%CI (68.3–98.8) among ILs the
overall sensitivity of smear microscopy was 51.0 %, 95 %
CI (40.6–61.4 %). Overall sensitivity for smear micros-
copy among PLs was 48.7 %, 95 % CI (37.0–60.4)
whereas for ILs was 60.0 %, 95%CI (36.1–80.9). The
overall sensitivity of smear microscopy was 39.3 %,
95%CI (21.5–59.4) and 55.9 %, 95%CI (43.3–67.9) among
HIV-positive and HIV-negative TB patients respectively.
By smear microscopy method, smear by ZN at PLs had
sensitivity of 55.1 %, 95 % CI (40.2–69.3) as compared to
LED-FM 37.7 %, 95%CI (19.4–57.6). For ILs, the sensi-
tivity for ZN smear microscopy was 58.3 %, 95%CI
(27.7–84.8) as compared to LED-FM 62.5 %, 95%CI
(24.5–59.4), Table 2. The overall specificity of smear mi-
croscopy 99.8 % 95 % C.I (99.4–100 %). The overall sen-
sitivity of smear microscopy was 55.7 %, 95 % C.I (42.4–
68.5–63.2 %) and 42.9 % (26.3–60.6 %) among ZN and
LED-FM using laboratories respectively, Table 2.
Incremental senstivity of Xpert assay over the smear
microscopy results
The overall incremental sensitivity (IS) of Xpert over
smear microscopy at all HF was 32.3 %, 95 % CI (23.1–
42.6 %). The overall IS of Xpert for either smear micros-
copy was 35.7 %, 95%CI (18.6–55.9) and 30.9 %, 95%CI
(20.2–43.3) among HIV-positive and HIV-negative indi-
viduals respectively. The IS of Xpert among PLs using
ZN was 32.7 %, 95 % CI (19.9–47.5); whereas for PLs
using LED-FM was 33.3, 95%CI (16.5–54.0). Among ILs
using ZN, the IS of Xpert was 25.0 %, 95%CI (5.5–57.2)
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as compared to ILs using LED-FM 37.5 %, 95%CI (8.5–
75.5), Table 2.
Discussion
In this cross-sectional study aimed at assessing the ac-
curacy of smear microscopy and the incremental
sensitivity of Xpert in presumptive pulmonary tuber-
culosis patients at tuberculosis laboratories in
Rwanda, we document low sensitivity of sputum
smear microscopy in tuberculosis diagnostic labora-
tories, particularly in peripheral laboratories. The
added value of Xpert was particularly important
among HIV-infected patients and for detection of
drug-resistant cases. We further confirm a significant
gain from Xpert when used as an initial diagnostic
test at health facility laboratories. For both health fa-
cility levels, the sensitivity of Xpert was significantly
higher than either smear microscopy methods. As ex-
pected, the sensitivities of both smear methods in-
cluding Xpert was higher among HIV-negative
participants. Replacing ZN smear microscopy with
LED-FM did not increase the detection of TB at both
health facility levels. The incremental detection of
Xpert from both smear methods was significantly
higher among PLs but not at ILs.
The sensitivity found in this study was however in the
range of findings from several studies where the sensitiv-
ities of conventional ZN microscopy ranged from 32 to
94 % and the sensitivities of fluorescence microscopy
ranged from 52 to 97 %, with the fluorescent method be-
ing on average 10 % more sensitive than light micros-
copy [5]. In contrast to earlier findings, however, the
current study did not find the sensitivity of LED-FM to
be statistically different from ZN (p = 0.371). These re-
sults differ from several previous studies where LED-FM
Fig. 1 Flow chart showing series of participants’ recruitment and the outcome of different tuberculosis testing methods used. +: Positive, -:
Negative, AFB: Acid Fast Bacilli, PTB: Pulmonary tuberculosis, ZN Lab: Ziehl Nelsen health facility laboratories-, LED-FM Lab: Light emitting
diode-fluorescence microscopy using health facility laboratories, NTM: Non-tuberculous Mycobacteria, cont.: contaminated






1 (15–35) 287 47.8
2 (36–55) 202 33.7





ZN smear positive 34 12.1
LED-FM smear positive 16 5.0
Xpert positive 82 13.7
Culture (MGIT and/or LJ) positive 96 16.0
MGIT mycobacterial growth indicator tube; LJ Lowenstein Jensen; LED-FM light
emitting diode fluorescence microscopy; ZN Ziehl Nelsen Xpert: Xpert MTB/RIF
test; HIV human immunodeficiency virus
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increases an average of 10 % of sensitivity over the con-
ventional ZN technique [6–10]. Other studies have
shown equal sensitivity or low specificity of LED-FM
compared to conventional ZN technique [9, 11–13].
In these studies, readers had no previous experience
with fluorescence microscopy, which is the most
likely explanation for sensitivity differences compared
with other studies and indicating the importance of
adapting training intensity according to the level of
operator proficiency. Our findings showed that smear
microscopy performed better at intermediate labora-
tories compared to peripheral; the sensitivity for LED-
FM 62.5 % vs. 37.0 %, p = 0.023 but not for ZN
58.3 % vs.55.1 %; p = 0.265. This may either be ex-
plained by the fact that LED-FM was implemented at
IL prior to peripheral and therefore technologists ac-
quired experience earlier compared to those at IL or
due to small sample size at the ILs.
The sensitivity of sputum smear microscopy in HIV-
infected participants was found to be low and are in
agreement with findings of previous studies, where it
ranges from 30 to 48 % [14–16]. The poor performance
of sputum smear microscopy in HIV patients can be ex-
plained in part by the fact that pulmonary tuberculosis
in these patients presents with paucibacillary TB and
lack cavitation [16].
The overall prevalence of smear negative pulmonary
tuberculosis using either smear method in HIV-infected
PTB presumptive participants was found to be high and
are in line with those of previous studies [17, 18]. The
level of immunosuppression among HIV-infected pa-
tients affects significantly the results of the sputum
smear; less severely immunocompromised HIV-positive
patients tend to have classic cavitary tuberculosis with
smear-positive results; as the level of immunocomprom-
ised increases with advancing HIV disease, atypical pul-
monary features predominate and smear examinations
prove less sensitive [17].
Although, the overall sensitivity of Xpert for the
detection of M. tuberculosis was slightly lower, its
specificity was consistent with those of previous
studies in a Cochrane review even when stratified by
HIV status [4]. The insignificant incremental sensi-
tivity of Xpert test over smear microscopy at ILs is
likely to be more explained by the small sample size
we had at these facilities.
The significant incremental sensitivity of Xpert from
either smear method at PLs supports the WHO recom-
mendation for using Xpert as an initial test for TB diag-
nosis [19]. Although the cost per test and compulsory
required maintenance of Xpert machine (annual calibra-
tion, replacement of modules, good and constant power
Table 2 Yield of smear microscopy versus Xpert among culture confirmed tuberculosis patients (n =96)
Xpert Sensitivity of







Overall SM at all HF
n = 96
positive 46 3 51.0 (40.6–61.4) 32.3 (23.1–42.6)
negative 31 16
SM in all HIV positive
n = 28
positive 10 1 39.3 (21.5–59.4) 35.7 (18.6–55.9)
negative 10 7
SM in all HIV negative
n = 68
positive 36 2 55.9 (43.3–67.9) 30.9 (20.2–43.3)
negative 21 9
SM at all PL
n = 76
positive 34 3 48.7 (37.0–60.4) 32.9 (22.5–44.6)
negative 25 14
SM at all IL
n = 20
positive 12 0 60.0 (36.1–80.9) 30.0 (11.9–54.3)
negative 6 2
SM at ZN PL
n = 49
positive 24 3 55.1 (40.2–69.3) 32.7 (19.9–47.5)
negative 16 6
SM at LED-FM PL
n = 27
positive 10 0 37.0 (19.4–57.6) 33.3 (16.5–54.0)
negative 9 8
SM at ZN IL
n = 12
positive 7 0 58.3 (27.7–84.8) 25.0 (5.5–57.2)
negative 3 2
SM at LED-FM IL
n = 8
positive 5 0 62.5 (24.5–91.5) 37.5 (8.5–75.5)
negative 3 0
LED-FM light emitting diode fluorescence microscopy; ZN Ziehl Nelsen Xpert: Xpert MTB/RIF test; HIV human immunodeficiency virus; CI confidence interval; SM
smear microscopy; IL intermediate laboratories; PL peripheral laboratories; SM smear microscopy
Ngabonziza et al. BMC Infectious Diseases  (2016) 16:660 Page 5 of 7
supply) may be not affordable by many poor resource
settings given the limited heath budgets [20], the savings
from increased case detection and timely initiation of
treatment due to early diagnosis, may be more cost ef-
fective in terms of supplies savings as well as patient sav-
ings from repeat facility visits. In addition, early
diagnosis may reduce the risk of TB transmission. It is
worth noting that the effectiveness of Xpert testing is
likely to depend on utilization as the test tends to be less
effective in low workload settings [21] as the low num-
bers of patients tested at IL could have affected the
strength of obtained significance measure.
Our study had some limitations; the level of immunosup-
pression for HIV positive PTB presumptive participants was
not measured (CD4); this could lead to poor classification
and consequently low differences in terms of smear sensitiv-
ity among HIV-infected participants. Secondary, the low
samples size obtained from ILs which probably masks the
obvious significant incremental detection of Xpert; among
the 600 participants of this study, only 210 (35 %) partici-
pants and 20 (20.8 %) pulmonary tuberculosis confirmed
cases were from ILs. The few numbers of HIV-infected pa-
tients in this study could not allow for meaningful compari-
son of incremental sensitivity by HIV-status, however,
significant Xpert IS among HIV-infected patients was previ-
ously documented [22]. Lastly, excluding samples which be-
came contaminated or positive for an NTM from the
analysis may have led to an under-estimation of the sensitiv-
ity of Xpert and smear microscopy, as tuberculosis cannot be
definitively excluded for these patients. TB-NTM coinfection
has been reported, but is supposed to be a relatively rare clin-
ical entity in Rwanda. However, excluding these participants
may have over-estimated the specificity of microscopy, as
smear-positive NTM infections were not taken into account
in the analysis, while the specificity of Xpert would probably
have been much less affected by the presence of NTM.
Conclusions
The findings from this study revealed a low detection
rate of both LED-FM and ZN smear microscopy at
health facility tuberculosis diagnostic laboratories in
Rwanda. This study revealed a low sensitivity of LED-
FM smear microscopy compared to ZN-microscopy
among PLs whereas for ILs, the senstivity of LED-FM
was higher than that of ZN microscopy, indicating dif-
ferences in skills requirements among microscopy
methods. This study revealed a signicant incremental de-
tection gained from Xpert. Hence, the data from this
study strongly support the conditional recommendation
of WHO for Xpert; where the Xpert may be used as ini-
tial diagnostic test in adults and children presumed to
have TB. Nevertheless, other studies of cost-effectiveness
and feasibility of the proposed strategy at large scale are
necessary.
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